Myeloproliferative Disease

Filter By:
26:46
Filmed at the US Focus on Myeloproliferat​ive Neoplasms and Myelodysplastic Syndromes 2014 meeting, this video discussion between Drs. Srdan Verstovsek, Ruben A. Mesa, Jason R. Gotlib, and Ramon V. Tiu outlines key learning points and summarizes take home messages from the presented content. This eng...
by:imedex | 19 views
02:12
Some people can be on Hydrea® (hydroxyurea) for an extended time period. But what are the long-term effects of this therapy? Dr. Bart Scott from Seattle Cancer Care Alliance discusses research for this treatment and the long-term safety of this medication. Get email alerts | http://www.p... Subscribe on YouTube |...
by:patientpower | 41 views
04:01
Is there a risk with suddenly stopping treatment that is working for you? Dr. David Snyder from City of Hope and Dr. Bart Scott from Seattle Cancer Care Alliance discuss the effects of discontinuing use of the JAK inhibitor, Jakafi®, and why tapering off of this medication is recommended. Get ema...
by:patientpower | 30 views
01:27
A common symptom of myeloproliferat​ive neoplasm (MPNs) is an enlarged spleen. So what causes an enlarged spleen in patients who have myelofibrosis, polycythemia vera or essential thrombocythemia? As part of our “Ask the Expert” series, Dr. Ross Levine from Memorial Sloan Kettering Cancer Center explains what is happening inside the bone marrow and ...
by:patientpower | 106 views
01:15
As part of our “Ask the Expert” series, Dr. Ross Levine from Memorial Sloan Kettering Cancer Center discusses chemical exposure as a potential cause of MPNs. Dr. Levine shares what researchers have learned about the Superfund site in Pennsylvania and Agent Orange. Get email alerts | http://www.p... Subscribe on YouTub...
by:patientpower | 99 views
02:55
Information about MPNs and JAK2 mutations abounds, including treatments that are appropriate for those with the mutation. But what if you’re JAK2 negative? Dr. Brady Stein from Northwestern Medicine explains gene mutations related to MPNs and MPN diagnosis. He shares which treatments tend to be effe...
by:patientpower | 75 views
05:37
What is the JAK2 mutation? What is a JAK inhibitor, and how does it work? Dr. Brady Stein, an MPN expert from Northwestern Medicine, explains what JAK2 is and how this gene relates to myeloproliferat​ive neoplasms (MPNs). He also describes JAK inhibitors, like ruxolitinib (Jakafi®), and the role that these agents play in the treatment of MPNs. Ge...
by:patientpower | 110 views
03:47
Myelofibrosis is a disorder of the bone marrow that disrupts normal production of blood cells causing excessive scarring of the bone marrow. So, is the goal of treatment to reduce scarring in the bone marrow? Watch Dr. Bart Scott from the Seattle Cancer Care Alliance as he shares his perspective on treatment for myelofibrosis and what he considers ...
by:patientpower | 118 views
19:41
Polycythemia vera is the most common of the myeloproliferat​ive neoplasms characterized by elevated hematocrit, splenomegaly and increased thrombotic risk. Together these conditions result in significant symptom burden and a reduced quality of life for these patients. The recent identification of gen...
by:imedex | 114 views
17:54
Polycythemia vera is the most common of the myeloproliferat​ive neoplasms characterized by elevated hematocrit, splenomegaly and increased thrombotic risk. Together these conditions result in significant symptom burden and a reduced quality of life for these patients. The recent identification of gen...
by:imedex | 102 views
Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Oncologist 
Different type of MD 
Nurse 
Other oncology Professional 
Patient/Advocate 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.


username:   password: remember me

Sign In

Username:
Password:
Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)